Form D · Biotechnology

Illumigyn Ltd.

Neve Ilan, L3 · CIK 0001688772

Offering snapshot reported Nov 21, 2016 · SEC filing

Reported sold
$2M
Offering amount: $5M
Investors reported
36
Form D · investor count
Minimum accepted
$15K
Reported outside-investor minimum
First sale
Nov 9, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 21, 2016Initial$2,000,446No comparison36SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$500K
Finders' fees
$0
Form D file number
021-274847
The sales commission reported above is based on the maximum offering amount. The Placement Agent is also entitled to receive warrants equal to 10% of the aggregate number of shares sold in the offering, and to reimbursement of certain fees and expenses.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
National Securities Corporation7569

Source: Form D, filed Nov 21, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Morry Blumenfeld Director
Jacob Bortman Director
Gadi Ganon Executive
Lior Greenstein Director, Executive
Ariel Katz Executive
Moshe Moalem Director
Richard Stone Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Communication Center
Neve Ilan, L3, 908500